Welcome to our dedicated page for OKYO PHARMA news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO PHARMA stock.
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage, ophthalmology-focused biopharmaceutical company developing novel therapies for neuropathic corneal pain (NCP), dry eye disease, and other ocular inflammatory conditions. Its news flow centers on the progress of its lead investigational drug candidate, urcosimod, and related clinical, regulatory, and corporate developments.
Visitors to this news page can review company-issued announcements about Phase 2 clinical trial results, including data showing reductions in neuropathic corneal pain and exploratory findings on corneal nerve structure in NCP patients treated with urcosimod. OKYO also reports on earlier Phase 2 results in dry eye disease, where urcosimod demonstrated statistically significant outcomes on multiple endpoints in a 240-patient trial.
In addition to clinical data, OKYO’s news releases cover planned development milestones such as the registration pathway and a proposed multiple-ascending-dose, multi-center trial in approximately 100 NCP patients, as well as references to urcosimod’s Fast-Track designation and anticipated regulatory interactions. Corporate communications include participation in ophthalmology and life science conferences, such as the Ophthalmology Innovation Summit and BIO-Europe, where management presents updates on urcosimod and the company’s pipeline.
Investors can also find announcements related to share acquisitions by Panetta Partners Limited, an entity with a beneficial interest held by OKYO’s Executive Chairman, as disclosed in both news releases and accompanying Form 6-K filings. Together, these updates provide a view into how OKYO is advancing urcosimod as a potential first-in-class therapy for neuropathic corneal pain and dry eye disease, and how it communicates key milestones to the market.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that Panetta Partners Limited acquired 5,800,000 ordinary shares at £0.0625 each on May 19, 2022. This purchase increases Gabriele Cerrone's beneficial interest from 39.64% to 40.06%. However, dilution from a recent offering reduces his holdings to 39.08%. The company's focus on developing novel molecules for treating inflammatory dry eye diseases remains ongoing, highlighting its commitment to addressing significant medical needs in the eye care market.
OKYO Pharma announced the closing of its public offering of 625,000 American Depository Shares (ADSs) at $4.00 per share, totaling $2.5 million in gross proceeds. The funds will be utilized to advance the IND filing for OK-101 to treat dry eye disease (DED), support an initial Phase 2 clinical trial, and for general corporate purposes. ThinkEquity served as the sole book-running manager. This offering follows the effective registration statement filed with the SEC on May 16, 2022.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, purchased 25,000 American Depository Shares (ADS) at $3.8749 each on May 17, 2022. This transaction increased Cerrone's beneficial interest from 39.52% to 39.64%. However, with an upcoming offering closing on May 19, 2022, his stake will be diluted to 38.50%. The ADS represents 65 ordinary shares, and the transaction occurred on NASDAQ.
OKYO Pharma Limited has announced the pricing of its underwritten initial public offering (IPO) of American Depositary Shares (ADSs) on the Nasdaq Capital Market. The company will issue 625,000 ADSs at $4.00 each, raising approximately $2.5 million in gross proceeds. The offering is expected to close on May 19, 2022. Funds will be used for advancing clinical trials and general corporate needs. The total number of Ordinary Shares after the offering will reach 1,415,040,468.
OKYO Pharma Limited has announced a public offering of 625,000 American Depositary Shares (ADSs) at $4.00 each, expected to raise approximately $2,500,000. An additional 93,750 ADSs may be purchased by underwriters to cover over-allotments. The offering is set to close on May 19, 2022, pending customary conditions. Proceeds will fund the IND filing for OK-101 targeting Dry Eye Disease (DED) and support an initial Phase 2 clinical trial. The ADSs will begin trading on Nasdaq under the symbol ‘OKYO’ from May 17, 2022.